瓦尔内瓦疫苗

最新新闻

• Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2025/1/23
• 评级变动
  Guggenheim Initiates Valneva(VALN.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2025/3/25
• 评级变动
  Jefferies Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2025/8/25
• 评级变动
  H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2025/2/19
• 评级变动
  Jefferies Maintains Valneva(VALN.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/24
• Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Valneva (VALN) Gets a Buy From H.C. Wainwright
  TipRanks · 2026/9/22
• 评级变动
  H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2025/4/16
• 评级变动
  Goldman Sachs Initiates Valneva(VALN.US) With Hold Rating, Announces Target Price $6.4
  \u5e02\u573a\u8d44\u8baf · 2024/11/21
• 评级变动
  H.C. Wainwright Initiates Valneva(VALN.US) With Buy Rating, Announces Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2025/8/19
• 评级变动
  Goldman Sachs Downgrades Valneva(VALN.US) to Sell Rating, Cuts Target Price to $4.9
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• 评级变动
  Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2025/11/21
• 评级变动
  Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2025/4/30
• 评级变动
  Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2025/5/9
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
  TipRanks · 2026/4/22
• 评级变动
  TR | OpenAI - 4o Maintains Valneva(VALN.US) With Hold Rating, Cuts Target Price to $9.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/26
• 评级变动
  Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/19
• TD Cowen Initiates Valneva(VALN.US) With Buy Rating, Announces Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。